The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo- controlled treatment with rupatadine 10 and 20 mg.
about
Updosing of Nonsedating Anti-histamines in Recalcitrant Chronic UrticariaChronic spontaneous urticaria: latest developments in aetiology, diagnosis and therapyLipid Mediators of Allergic Disease: Pathways, Treatments, and Emerging Therapeutic TargetsH1-antihistamine up-dosing in chronic spontaneous urticaria: patients' perspective of effectiveness and side effects--a retrospective survey studyUnmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report.Consensus statement on the management of urticaria.Rupatadine in Established Treatment Schemes Improves Chronic Spontaneous Urticaria Symptoms and Patients' Quality of Life: a Prospective, Non-interventional Trial.Diagnosis and treatment of urticaria and angioedema: a worldwide perspective.Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticariaRupatadine for the treatment of allergic rhinitis and urticaria.Pharmacological rationale for the treatment of chronic urticaria with second-generation non-sedating antihistamines at higher-than-standard doses.Rupatadine for the treatment of urticaria.Pharmacotherapy of chronic spontaneous urticaria.The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update.Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria.Update on rupatadine in the management of allergic disorders.Chronic spontaneous urticaria - a management pathway for patients with chronic spontaneous urticaria.Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects.Current and future therapies for treating chronic spontaneous urticaria.Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis.Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years.[Urticaria … and treatment fails].Comparative efficacy of non-sedating antihistamine updosing in patients with chronic urticaria.Selected urticaria patients benefit from a referral to tertiary care centres--results of an expert survey.Management of chronic spontaneous urticaria in real life--in accordance with the guidelines? A cross-sectional physician-based survey study.An open-label prospective clinical study to assess the efficacy of increasing levocetirizine dose up to four times in chronic spontaneous urticaria not controlled with standard dose.Levocetirizine and rupatadine in chronic idiopathic urticaria.Chronic spontaneous urticaria - a management pathway for patients with chronic spontaneous urticaria
P2860
Q26747012-56EF62AC-C029-43A6-AE0C-80A212B3CFEBQ26777088-48681670-3A4D-43C0-9FD2-B9A95354127BQ28276574-36DF70B7-779F-4667-B274-4761E1D0CAE5Q28740885-A72CB050-9D3F-4D07-AF25-B469850CE068Q34150295-D4B1B558-F4A7-4B5A-920A-C70EFB391126Q35564594-1D89D883-18C1-4769-9742-3CA01213F916Q36359983-4D191729-34B5-451F-8BAC-E64915332A0DQ36834774-D47C4CE3-36FD-4358-B168-E07D1FD51CAAQ37642908-517377B6-7EB5-41AF-8CFA-FC578EF3EBA5Q37821491-33D1BBCF-4953-4996-9C31-1C162E02469CQ37907381-369824DC-C46C-49AC-95B1-6358237844BBQ38117399-AE2B7986-F38F-43F0-B4D6-12B2F76DE9F1Q38160274-FF3D43DF-1180-4573-B945-F06DFCD552D7Q38208428-6B81B16E-4722-4EE5-AEB7-BC8A3CF435F4Q38217720-BD0204C5-4E74-4BBE-B6B9-346414EB712EQ38285821-D3A7AC38-80F4-4C6B-AE0A-688B58549F64Q38445637-CA63D6E7-19DE-4FAF-BBBE-27D21FB4C999Q38539741-CA91A1FB-9704-458F-BC07-039FBA6FED94Q38751342-6E2DC124-9629-4291-800B-175B04C65D32Q38847557-526AB3DD-0AD5-4C39-A342-D53F769068C0Q39185025-5833AB43-EC54-406A-90C8-93E3B0C61994Q39222155-48AFEB0F-2BB8-4582-AD30-C18FFD4A0F0BQ43190363-B99CBAAF-1BB2-4553-AEE7-4C4245F0EED4Q43447828-33DF05C2-2CB6-494B-A829-AA0893633A05Q45223665-215A5813-0A51-4F96-A832-68BFD52C47D7Q47635223-AB1D6532-BC1E-45C8-89D8-AF82EA88263DQ48055791-B3C159F2-9527-43FB-8D4F-88A62BD17520Q56637625-6149C081-70CB-4E38-8E91-CAD6768D9E6E
P2860
The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo- controlled treatment with rupatadine 10 and 20 mg.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
The use of a responder analysi ...... with rupatadine 10 and 20 mg.
@en
The use of a responder analysi ...... with rupatadine 10 and 20 mg.
@nl
type
label
The use of a responder analysi ...... with rupatadine 10 and 20 mg.
@en
The use of a responder analysi ...... with rupatadine 10 and 20 mg.
@nl
prefLabel
The use of a responder analysi ...... with rupatadine 10 and 20 mg.
@en
The use of a responder analysi ...... with rupatadine 10 and 20 mg.
@nl
P2093
P1476
The use of a responder analysi ...... with rupatadine 10 and 20 mg.
@en
P2093
A Giménez-Arnau
I Izquierdo
P304
P356
10.1111/J.1468-3083.2009.03289.X
P577
2009-05-18T00:00:00Z